ArticleFrontiers in oncology2026
Efficacy and safety of Shenqi Fuwei granule combined with perioperative regimen in the treatment of locally advanced gastric cancer: a randomized, double-blind, placebo-controlled multicenter clinical trial protocol.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07098026 (Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer: A Multicenter Randomized Controlled Clinical Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While the introduction of neoadjuvant therapy has innovated perioperative treatment strategies for locally advanced gastric cancer (LAGC), preventing postoperative recurrence and metastasis remains a key clinical challenge. Previous research has indicated that Shenqi Fuwei granules (SQFWG), a Traditional Chinese medicine (TCM) prescription, possesses anti-gastric cancer properties. However, evidence from perioperative intervention studies is lacking. Our trial aims to evaluate the efficacy and safety of SQFWG combined with perioperative therapy in reducing postoperative recurrence and metastasis in LAGC, to explore clinical characteristics of the benefiting population, and to provide an evidence base for developing treatment protocols. Methods: This is a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial. We plan to recruit 286 perioperative LAGC patients from multiple hospitals in China. Participants will be randomly assigned (1:1) using a central interactive web response system with allocation concealment, stratified by the use of neoadjuvant chemotherapy ± immunotherapy, to either the control group (n=143, placebo containing 5% SQFWG) or the experimental group (n=143, SQFWG). Both groups will concurrently receive perioperative treatment (chemotherapy ± immunotherapy). Follow-up assessments will be conducted every 3 months for 3 years after treatment completion or upon reaching an endpoint event. The primary efficacy endpoint is event-free survival. Secondary outcomes include overall survival, cumulative 1-/2-/3-year recurrence and metastasis rates, surgical conversion rate, quality of life, and safety. At the same time, prespecified subgroup analyses will be performed according to the use of immunotherapy and the type of chemotherapy regimen, and the clinical applicability of SQFWG will be further explored. Discussion: To our knowledge, this is one of the first multicenter randomized double-blind placebo-controlled trials evaluating the efficacy of SQFWG in perioperative LAGC. This trial is expected to provide high-level evidence for the role of TCM in perioperative comprehensive management of LAGC. Clinical trial registration: https://www.ClinicalTrials.gov, identifier NCT07098026, ITMCTR2025001212.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.